ArticleSensors (Basel, Switzerland)2026
Beyond Euglycemia: Case Studies Using Continuous Glucose Monitoring in Elite Athletes Without Diabetes During Record Athletic Events.
Article in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucose data regarding extreme elite performances in athletes without diabetes remains limited. The purpose is to characterize continuous glucose monitoring (CGM) responses in elite athletes across distinct high-performance contexts. This descriptive case series includes three separate elite athletes who used a CGM during their respective sporting events. The first is an ultra-endurance relay cycling world-record performance (Race Across the West, RAW), the second is a continuous high-intensity Everesting Challenge cycling record attempt, and the third is a maximal constant-weight no-fins breath-hold depth dive performed in international competition. Glycemic outcomes, as measured by CGM, included mean, maximum, and minimum glucose, glucose standard deviation (SD), and the percentage of time in tight glucose range (TITR: 70-140 mg/dL; 3.9-7.8 mmol/L), time below range (TBR: <70 mg/dL; <3.9 mmol/L), and time above range (TAR140: >140 mg/dL; >7.8 mmol/L). Other performance data, including peak power, heart rate, and lactate, are also provided where available. During the RAW challenge lasting 44 h and 20 min, mean glucose was 91 ± 23.2 mg/dL (mean ± SD) with 9.15% TBR and 35.58% TITR during cycling and 115 ± 24.7 mg/dL with 9.11% TBR and 43.16% TITR during resting periods. In contrast, the Everesting Challenge cycling record attempt demonstrated a persistently elevated glucose profile (160 ± 5.7 mg/dL), minimal variability (CV 3.5%), and 100% TAR140. Following the maximal breath-hold depth dive, interstitial glucose was 100% TAR140 during recovery (187 ± 18.5 mg/dL), alongside marked elevations in blood lactate concentrations (peak 13.4 mmol/L). The series of case studies demonstrate that substantial deviations from traditional euglycemic ranges are common during elite performance in athletes without diabetes. Interpretation of CGM data in athletic settings should therefore be performance- and context-specific rather than based on clinical glycemic thresholds.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.